Read by QxMD icon Read

Fusion biopsy prostate

Nienke L Hansen, Brendan C Koo, Ferdia A Gallagher, Anne Y Warren, Andrew Doble, Vincent Gnanapragasam, Ola Bratt, Christof Kastner, Tristan Barrett
OBJECTIVES: To investigate the value of second-opinion evaluation of multiparametric prostate magnetic resonance imaging (MRI) by subspecialised uroradiologists at a tertiary centre for the detection of significant cancer in transperineal fusion prostate biopsy. METHODS: Evaluation of prospectively acquired initial and second-opinion radiology reports of 158 patients who underwent MRI at regional hospitals prior to transperineal MR/untrasound fusion biopsy at a tertiary referral centre over a 3-year period...
October 24, 2016: European Radiology
Thais Caldara Mussi, Yves Bohrer Costa, Marcos Takeo Obara, Marcos Roberto Gomes de Queiroz, Rodrigo Gobbo Garcia, José Antonio Domingos Cianciarulo Longo, Gustavo Caserta Lemos, Ronaldo Hueb Baroni
Objective: To describe the imaging findings of prostatic tumors nonadenocarcinoma on multiparametric magnetic resonance imaging. Methods: A total of 200 patients underwented multiparametric magnetic resonance imaging of the prostate for screening for prostate cancer, from August 2013 to September 2014, followed by biopsy with ultrasound/magnetic resonance imaging fusion. Results: We found three pathologic proved cases of prostatic pure leiomyomas (0...
July 2016: Einstein
Bernardo Rocco, Luca Boeri
No abstract text is available yet for this article.
November 2016: BJU International
J Cohen, C Andre, P Mozer
Prostate cancer is the first cancer and the second cause of cancer death in men in France. It is now a major public health issue, particularly given the increase of life expectancy. If screening is based on blood PSA and clinical examination (DRE), diagnosis requires the histological analysis of prostate samples. In current clinical routine, these biopsies are performed by endorectal through ultrasound guidance. In most cases, the cancer is not visible in the ultrasound image and the latter is used to make a dozen samples (or core), distributed as best as possible in the prostate...
October 14, 2016: Progrès en Urologie
Rahul Mannan, Tejinder Singh Bhasin, Mridu Manjari, Gagandeep Singh, Puneet Kaur Bhatia, Sonam Sharma
BACKGROUND: Prostate carcinoma is the second leading cause of cancer-related deaths in males worldwide. The burden is expected to grow 1.7 million new cases and 499,000 new deaths by 2030. In developing countries such as India, prostate carcinoma will show an increase by 140% in the next few years. Although the diagnosis of prostate carcinoma can usually be made on histological features, now a days many immunohistochemical (IHC) markers are used to distinguish it from benign mimickers as well as in predicting prognosis and treatment...
October 2016: Indian Journal of Pathology & Microbiology
Wei Phin Tan, Andrew Mazzone, Stephanie Shors, Nency Antoine, Shahid Ekbal, Narendra Khare, Charles McKiel, Dennis Pessis, Leslie Deane
INTRODUCTION AND OBJECTIVE: The Prostate Imaging Reporting and Data System (PI-RADS) score was developed to evaluate lesions in the peripheral and transition zone on multiparametric magnetic resonance imaging (mpMRI) of the prostate. We aim to determine if the PI-RADS scoring system can be used to evaluate central zone lesions on mpMRI. MATERIALS AND METHODS: A retrospective review of 73 patients who underwent mpMRI/ultrasound (US) fusion-guided biopsy of 143 suspicious lesions between February 2014 and October 2015 was performed...
September 27, 2016: Urologic Oncology
Z E Zhou, W G Yan, Y Zhou, Z G Ji, H Z Li
Prostate cancer is currently diagnosed by prostate biopsy performed by the transrectal ultrasound-guided technique. However, overdetection of clinical insignificant tumours and missed detection of clinical significant tumours have become problematic. MRI of the prostate, particularly if performed with multiparametric imaging, is capable of detecting clinical significant prostate cancer, which has brought the opportunity to use those images as targets for needle biopsy. Three methods of fusing MRI for targeted biopsy have been recently described: MRI-ultrasound fusion, MRI-MRI fusion ('in-bore' biopsy) and cognitive fusion...
October 1, 2016: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
Talisa Ross, Kamran Ahmed, Nicholas Raison, Ben Challacombe, Prokar Dasgupta
INTRODUCTION: Prostate specific antigen is a marker for prostate cancer and a key diagnostic tool, yet when to refer patients with a borderline PSA is currently unclear. This review describes how to assess a patient with borderline PSA and provides an algorithm for management. METHODS: Current literature on reference values, factors affecting PSA, indications for referral, non-invasive investigations and the role of MRI were reviewed. Medline and EMBASE were searched using MeSH terms...
September 27, 2016: International Journal of Clinical Practice
Nima Nassiri, Daniel J Margolis, Shyam Natarajan, Devi S Sharma, Jiaoti Huang, Frederick J Dorey, Leonard S Marks
PURPOSE: To determine rate of upgrading to Gleason score (GS) ≥ 4+3, using targeted biopsy for diagnosis and monitoring, in men undergoing active surveillance (AS) of prostate cancer (CaP). MATERIALS AND METHODS: Subjects were all 259 men (196 with GS 3+3 and 63 with GS 3+4) who were diagnosed by MRI/US fusion-guided biopsy (2009-2015) and who underwent subsequent fusion biopsy for as long as 4 years of AS. Primary endpoint was discovery of GS ≥ 4+3 CaP. Follow-up biopsies included targeting of positive sites, which were tracked in an Artemis device...
September 14, 2016: Journal of Urology
M J Scheltema, K J Tay, A W Postema, D M de Bruin, J Feller, J J Futterer, A K George, R T Gupta, F Kahmann, C Kastner, M P Laguna, S Natarajan, S Rais-Bahrami, A R Rastinehad, T M de Reijke, G Salomon, N Stone, R van Velthoven, R Villani, A Villers, J Walz, T J Polascik, J J M C H de la Rosette
PURPOSE: To codify the use of multiparametric magnetic resonance imaging (mpMRI) for the interrogation of prostate neoplasia (PCa) in clinical practice and focal therapy (FT). METHODS: An international collaborative consensus project was undertaken using the Delphi method among experts in the field of PCa. An online questionnaire was presented in three consecutive rounds and modified each round based on the comments provided by the experts. Subsequently, a face-to-face meeting was held to discuss and finalize the consensus results...
September 16, 2016: World Journal of Urology
Francesco Porpiglia, Stefano DE Luca, Roberto Passera, Matteo Manfredi, Fabrizio Mele, Enrico Bollito, Agostino DE Pascale, Marco Cossu, Roberta Aimar, Andrea Veltri
AIM: To investigate if targeted prostate biopsy (TBx) has superior performance to standard untargeted biopsy (SBx) in determining the optimal agreement between biopsy and surgical Gleason Score (GS). PATIENTS AND METHODS: An analysis of our institutional longitudinal database identified 683 consecutive patients who underwent either SBx (18-20 standardized transrectal ultrasound peripheral/transitional zone cores) or TBx alone (4-6 cores for each multiparametric magnetic resonance suspicious lesion, Prostate Imaging Reporting and Data System [(PI-RADS)≥3] after a previous negative first SBx...
September 2016: Anticancer Research
Matthias Haas, Karsten Günzel, Kurt Miller, Bernd Hamm, Hannes Cash, Patrick Asbach
Prostate volume in multiparametric MRI (mpMRI) is of clinical importance. For 3-Tesla mpMRI without endorectal coil, there is no distinctive standard for volume calculation. We tested the accuracy of the ellipsoid formula with planimetric volume measurements as reference and investigated the correlation of gland volume and cancer detection rate on MRI/ultrasound (MRI/US) fusion-guided biopsy. One hundred forty-three patients with findings on 3-Tesla mpMRI suspicious of cancer and subsequent MRI/US fusion-guided targeted biopsy and additional systematic biopsy were analyzed...
September 15, 2016: Urologia Internationalis
Karsten Günzel, Matthias Haas, Andreas Maxeiner, Carsten Stephan, John Buckendahl, Patrick Asbach, Kurt Miller, Carsten Kempkensteffen, Hannes Cash
OBJECTIVE: Evaluating the predictive factors that enable identifying men in which a sole MRI/ultrasound (MRI/US) fusion-guided targeted biopsy (TB) detects the maximal prostate cancer (PCa) risk group. PATIENTS AND METHODS: Retrospective analysis of 251 consecutive patients who received a sensor-based, real-time MRI/US TB in combination with a 10-core systematic biopsy (SB) between August 2013 and July 2015. Univariate and multivariate binary regression analyses were performed to evaluate the predictors for equal/superior detection of the PCa risk group by TB compared to SB...
September 13, 2016: Urologia Internationalis
T P Frye, A K George, A Kilchevsky, M Maruf, M M Siddiqui, M Kongnyuy, A Muthigi, H Han, H L Parnes, M Merino, P Choyke, B Turkbey, B Wood, P A Pinto
BACKGROUND: Active surveillance (AS) is an established option for men with low risk prostate cancer (CaP). Multiparametric-MRI (MP-MRI) with MRI-TRUS fusion-guided biopsy (FB) may better identify patients for AS, compared to systematic 12-core biopsy (SB), due to improved risk stratification. The performance of MP-MRI in following men on AS with visible lesions is unknown. We aim to evaluate MP-MRI and FB in monitoring men on AS. METHODS: Retrospective review of men from 2007-2015 with CaP on AS with MRI visible lesions monitored by MP-MRI and FB were included...
September 6, 2016: Journal of Urology
Eugenio Martorana, Giacomo Maria Pirola, Michele Scialpi, Salvatore Micali, Andrea Iseppi, Luca Reggiani Bonetti, Shaniko Kaleci, Pietro Torricelli, Giampaolo Bianchi
OBJECTIVE: To demonstrate the association between magnetic resonance imaging (MRI) estimated lesion volume (LV), prostate cancer detection and tumour clinical significance, evaluating this variable alone and matched with Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) score. PATIENTS AND METHODS: We retrospectively analysed 157 consecutive patients, with at least one prior negative systematic prostatic biopsy, who underwent transperineal prostate MRI/ultrasonography fusion-targeted biopsy between January 2014 and February 2016...
September 8, 2016: BJU International
Geraldine N Tran, Michael S Leapman, Hao G Nguyen, Janet E Cowan, Katsuto Shinohara, Antonio C Westphalen, Peter R Carroll
BACKGROUND: Fusion biopsy using multiparametric magnetic resonance imaging (MRI) and transrectal ultrasound has demonstrated favorable detection rates of high-grade prostate cancer (PCa) among previously undiagnosed men. However, the diagnostic yield among men with active surveillance (AS) remains undefined. OBJECTIVE: To determine the utility of MRI-ultrasound fusion biopsy during AS by reporting rates of PCa upgrading and comparing findings with systematic biopsy...
August 29, 2016: European Urology
Antoinette Birs, Peter H Joyce, Zoran J Pavlovic, Alexander Lim
PURPOSE:  Transrectal ultrasound (TRUS) has been the gold standard of imaging for diagnosing prostate cancer for decades but is plagued by user error and undersampling. We aim to explore imaging modalities that are now being used in combination or alone for screening, diagnosis, and/or active surveillance of prostate cancer. METHODS: A PubMed literature search was performed to include articles published up to April 2016. Data were extracted and analyzed. RESULTS: Several large-scale studies have found an increased cancer detection rate in MRI-targeted lesions with an improved ability to target anterior lesions as well as an increased cancer detection in high-risk cancers using fusion platforms vs TRUS alone...
2016: Curēus
David A Woodrum, Krzysztof R Gorny, Bernadette Greenwood, Lance A Mynderse
Prostate cancer is the most commonly diagnosed noncutaneous cancer and second-leading cause of death in men. Many patients with clinically organ-confined prostate cancer undergo definitive, curative treatment of the whole gland with either radical prostatectomy or radiation therapy. However, many men are reluctant to take the definitive step due to potential morbidity associated with either therapy. A growing interest in active surveillance or focal therapy has emerged as realistic alternatives for many patients...
September 2016: Seminars in Interventional Radiology
Akhil Muthigi, Arvin K George, Abhinav Sidana, Michael Kongnyuy, Richard Simon, Vanessa Moreno, Maria J Merino, Peter L Choyke, Baris Turkbey, Bradford J Wood, Peter A Pinto
PURPOSE: Multiparametric magnetic resonance imaging and fusion biopsy detect more high risk prostate cancer and less low risk prostate cancer than systematic biopsy. However, there remains a small subset of patients in whom systematic biopsy captures higher grade disease than fusion biopsy. We sought to identify potential mechanisms of the failure of fusion biopsy in the detection of clinically significant prostate cancer. MATERIALS AND METHODS: We reviewed a prospectively maintained database of patients who underwent multiparametric magnetic resonance imaging followed by fusion biopsy and systematic biopsy from 2007 to 2014...
August 28, 2016: Journal of Urology
Jennifer B Gordetsky, John V Thomas, Jeffrey W Nix, Soroush Rais-Bahrami
Recent studies have suggested that multiparametric magnetic resonance imaging (MRI)/ultrasound (US) fusion-guided prostate biopsy can detect more clinically significant prostate cancers, which could impact patient management. As many of the studies evaluating MRI/US fusion-guided prostate biopsy were conducted in specialized quaternary care centers, the question remains whether this technology is transferable to general practice. Our study assesses the diagnostic ability of MRI/US fusion-guided prostate biopsy compared with standard biopsy in the new era of prostate cancer Grade Grouping...
August 29, 2016: American Journal of Surgical Pathology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"